OBJECTIVE: To determine if smoking, a known risk factor for a number of cancers including cervical cancer, is associated with poor prognosis in patients with locally advanced cervical carcinoma treated with chemoradiation. METHODS:Patients with primary, previously untreated, histologically confirmed stage II-B, III-B or IV-A cervical carcinoma participated in a Gynecologic Oncology Group (GOG) phase III study (GOG 165) and were randomly allocated to receive radiation plus either cisplatin or 5-fluorouracil. Smoking behavior was ascertained using an administered questionnaire and by quantifying urine cotinine concentration. Disease progression was defined as a >or=50% increase in the cross product of the existing tumor compared with previous assessments. Patients were followed until death. RESULTS: Of 328 enrolled patients, 12 were ineligible, one was inevaluable for reported smoking status and 40 others were inevaluable for cotinine-derived smoking status. Among evaluable patients, 133 (42%) were reported smokers and 111 (40%) were cotinine-derived smokers. The kappa for agreement between the groups was 0.872 (P<0.01). Compared with non-smokers, median survival was 15 months shorter for reported smokers and 20 months shorter for cotinine-derived smokers (P<0.01). After adjusting for covariates, a significant increase in the risk of death (but not disease progression) was observed for reported smokers (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.01-2.27; P=0.04) and cotinine-derived smokers (HR: 1.57; 95% CI: 1.03-2.38; P=0.04). CONCLUSIONS: Smoking predicts worse overall survival in women with locally advanced cervical carcinoma treated with chemoradiation.
RCT Entities:
OBJECTIVE: To determine if smoking, a known risk factor for a number of cancers including cervical cancer, is associated with poor prognosis in patients with locally advanced cervical carcinoma treated with chemoradiation. METHODS:Patients with primary, previously untreated, histologically confirmed stage II-B, III-B or IV-A cervical carcinoma participated in a Gynecologic Oncology Group (GOG) phase III study (GOG 165) and were randomly allocated to receive radiation plus either cisplatin or 5-fluorouracil. Smoking behavior was ascertained using an administered questionnaire and by quantifying urine cotinine concentration. Disease progression was defined as a >or=50% increase in the cross product of the existing tumor compared with previous assessments. Patients were followed until death. RESULTS: Of 328 enrolled patients, 12 were ineligible, one was inevaluable for reported smoking status and 40 others were inevaluable for cotinine-derived smoking status. Among evaluable patients, 133 (42%) were reported smokers and 111 (40%) were cotinine-derived smokers. The kappa for agreement between the groups was 0.872 (P<0.01). Compared with non-smokers, median survival was 15 months shorter for reported smokers and 20 months shorter for cotinine-derived smokers (P<0.01). After adjusting for covariates, a significant increase in the risk of death (but not disease progression) was observed for reported smokers (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.01-2.27; P=0.04) and cotinine-derived smokers (HR: 1.57; 95% CI: 1.03-2.38; P=0.04). CONCLUSIONS: Smoking predicts worse overall survival in women with locally advanced cervical carcinoma treated with chemoradiation.
Authors: Diana S Hoover; Claire A Spears; Damon J Vidrine; Joan L Walker; Ya-Chen Tina Shih; David W Wetter Journal: Am J Health Behav Date: 2019-05-01
Authors: Erica N Peters; Essie Torres; Benjamin A Toll; K Michael Cummings; Ellen R Gritz; Andrew Hyland; Roy S Herbst; James R Marshall; Graham W Warren Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Jamie S Ostroff; Jack E Burkhalter; Paul M Cinciripini; Yuelin Li; Mariya P Shiyko; Cho Y Lam; Jennifer L Hay; Lara K Dhingra; Jennifer Lord-Bessen; Susan M Holland; Ruth Manna Journal: Health Psychol Date: 2013-07-29 Impact factor: 4.267
Authors: Ann L Coker; Christopher P DeSimone; Katherine S Eggleston; Claudia Hopenhayn; Jaclyn Nee; Thomas Tucker Journal: Gynecol Oncol Date: 2008-11-25 Impact factor: 5.482
Authors: Nelson A Morales; Michelle A Romano; K Michael Cummings; James R Marshall; Andrew J Hyland; Alan Hutson; Graham W Warren Journal: Cancer Causes Control Date: 2013-04-04 Impact factor: 2.506